{"name":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","slug":"mcneil-consumer-specialty-pharmaceuticals-a-division-of-mcneil-ppc-inc","ticker":"","exchange":"","domain":"","description":"McNeil Consumer & Specialty Pharmaceuticals, a division of McNeil-PPC, Inc., is a leading specialty pharmaceutical company focused on developing and marketing over-the-counter (OTC) medications and prescription drugs. The company is known for its commitment to improving patient health through innovative products and therapies.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Methylphenidate extended-release; Atomoxetine","genericName":"Methylphenidate extended-release; Atomoxetine","slug":"methylphenidate-extended-release-atomoxetine","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults","status":"marketed"},{"name":"methylphenidate hydrochloride extended-release tablets","genericName":"methylphenidate hydrochloride extended-release tablets","slug":"methylphenidate-hydrochloride-extended-release-tablets","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_3"}]}],"pipeline":[{"name":"Methylphenidate extended-release; Atomoxetine","genericName":"Methylphenidate extended-release; Atomoxetine","slug":"methylphenidate-extended-release-atomoxetine","phase":"marketed","mechanism":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity, while atomoxetine is a selective norepinephrine reuptake inhibitor.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adults"],"catalyst":""},{"name":"methylphenidate hydrochloride extended-release tablets","genericName":"methylphenidate hydrochloride extended-release tablets","slug":"methylphenidate-hydrochloride-extended-release-tablets","phase":"phase_3","mechanism":"Methylphenidate hydrochloride is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRnVMQ0pzQUdBWGtncGNueFJVUXQxQ1hNM2R1elJuOHJGY1JrRWN5VjM5NzBkYUVjbGE3OERDc1dhUHh6aUtCaFloSUNOSjkzRWpzbTA1NmppaGYtX1MwUEkta1ZjTktSYjJob3l4a1BWWnR5aDIzRWFLNmhoNW5kWS1sOUkyV3QyZ2g3RW14M0U0V3FLOWN0bklNRm1tdFVsSlh1czlvRFRaaFU?oc=5","date":"2017-05-25","type":"pipeline","source":"Fierce Pharma","summary":"Johnson & Johnson to pay $33M to resolve allegations of slipshod manufacturing - Fierce Pharma","headline":"Johnson & Johnson to pay $33M to resolve allegations of slipshod manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE4yV0R0WGk1aV9ZVDYtWi1FS04zSU13ZXdQekJTdXBUSkpaeWk1cGFicHQxNzZxZ2ZzTHZRdmVvMm1VOHptaEFRN1ZUWDZhMS0tVmRCM0RjWldoM1gzMFZwb2M1bTV4X0VnRnowWXlUVGl6WWJGd1h2Ml9jTnBQRDg?oc=5","date":"2013-09-20","type":"pipeline","source":"ProPublica","summary":"Use Only as Directed - ProPublica","headline":"Use Only as Directed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNV19sU3MzTWVsdF9HU2N1WnAzOU05eDdZd2hGRTk0TldBWVNJeEN4Q3ZleHYzRy1vczRkbFZmX01Zbmdpd09SSEltVm5xRE9XYnh5bW5OaktHWFZCcHoybDJVNkJsckFOdVVmQ196QzVCSUk4c1VXTU9NbG1hZGtFME9BeXc1eDNGY3padmlR?oc=5","date":"2011-09-29","type":"deal","source":"Contract Pharma","summary":"McNEIL-PPC Acquires J&J-Merck Consumer J - Contract Pharma","headline":"McNEIL-PPC Acquires J&J-Merck Consumer J","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBlVXR0bllSNGRwUEVYLXl5Yk40TnFGNXM5Y205NTlvQjdoQnJXODROSXVmektsYkQ2U3hvdEtDR244dkk0Ykc2QkRmZWRHNGduZFEwOXRqVW0xUGNEQWlSUE9pSUt3Q2tGaU5mYVJYQmVsZHVYa3c?oc=5","date":"2011-07-29","type":"pipeline","source":"Pharmacy Times","summary":"Maximum Dose for Tylenol Lowered - Pharmacy Times","headline":"Maximum Dose for Tylenol Lowered","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}